Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment

Inclusion Criteria: * Understand the whole test process, voluntary and signed informed consent form * Men and women aged 35 to 70 years old * 20≤BMI\<35 Kg/m2 * Diagnosed with type 2 diabetes * Undergoing metformin(Dose not less than 1000 mg/day)in combination with basal insulin injection once a day * HbA1c7.0-11% * Patients should be able to self blood glucose monitoring Exclusion Criteria: * sulfonylureas,glinides,TZDs use within 3 months before the study * Pregnant or lactating women * A history of ketoacidosis * Allergy to sulfonylureas or sulfa drug patients * Apparent dysfunction of liver and kidney patients(ALT\>2 times upper normal limit,serum creatinine\>1.2 times upper normal limit) * Poor blood pressure control(systolic pressure\>180mmHg or diastolic blood pressure\>110mmHg) * heart disease,cardiac insufficiency,unstable angina pectoris,ECG indicates left ventricle hypertrophy,severe anemia(Hb\<9.0g/d1) * Severe diabetic nerve complications(ulcer of lower limb,neurogenic bladder) * BMI\<20 orBMI≥35kg/m2 * Alcohol or drug abuse ,or can't collaborate due to mental disorder * Digestion and absorption function obstacle or Other endocrine disorders * Other chronic diseases required long-term glucocorticoid treatment